Abstract
Quality-of-life (QOL) assessment is becoming increasingly important in the evaluation of the impact of disease and the effect of therapy. This is particularly so for irritable bowel syndrome (IBS) where there is often a tendency for a chronic clinical course, but with no associated mortality. Instruments used to study quality of life may be generic or disease specific, and care needs to be taken to ensure that the instrument used has been adequately validated for the purpose intended. Several disease-specific instruments [Irritable Bowel Syndrome Quality of Life (IBS-QOL, IBSQOL) and Functional Digestive Disorders Quality of Life (FDDQL)], in addition to generic measures, are now available for use in IBS.
Quality of life in patients with IBS is surprisingly poor, particularly in the population seeking healthcare, where it can be compared with conditions which carry a high mortality, such as ischaemic heart disease, heart failure and diabetes mellitus. Pain severity appears to be an important factor in determining quality of life in IBS, although bowel disturbance and psychological difficulties are also likely to be important.
There is limited data on the effect of treatment of IBS on quality of life. Improvement has been reported with dietry modification, drug treatments and hypnotherapy. It is likely that, in the future, QOL measures will become increasingly used as secondary end-points in therapeutic trials in IBS.
References
Thompson WG, Longstreth GF, Drossman DA, et al. Functional bowel disorders and functional abdominal pain. Gut 1999; 45 Suppl. 2: 43–7
Talley NJ, Zinsmeister AR, Schleck CD, et al. Dyspepsia and dyspepsia subgroups: a population based study. Gastroenterology 1992; 102: 1259–68
Talley NJ, Weaver AL, Zinsmeister AR, et al. Onset and disappearance of gastrointestinal symptoms and functional gastrointestinal disorders. Am J Epidemiol 1992; 136: 165–77
Constitution of the World Health Organisation. Handbook of basic documents. 5th ed. Geneva: Palais des Nations, 1952
Testa MA, Simonson DC. Current concepts: assessment of quality of life outcomes. N Engl J Med 1996; 334 (13): 835–40
Irvine EJ. Quality of life: rationale and methods for developing a disease-specific instrument for inflammatory bowel disease. Scand J Gastroenterol 1993; 28 Suppl. 199: 22–7
Bech P. Quality of life measurements for patients taking which drugs? The clinical PCASEE perspective. Pharmacoeconomics 1995 Feb; 7 (2): 141–51
Lee OY, Fitzgerald LZ, Naliboff B, et al. Impact of advertisement and clinic populations in symptoms and perception of irritable bowel syndrome. Aliment Pharmacol Ther 1999; 13: 1631–8
Guthrie EA, Creed FH, Whorwell PJ, et al. Outpatients with irritable bowel syndrome: a comparison of first time and chronic attenders. Gut 1992; 33 (3): 361–3
Xuan J, Kirchdoerfer LJ, Boyer JG, et al. Effects of comorbidity on health related quality of life scores: an analysis of clinical trial data. Clin Ther 1999; 21 (2): 383–403
Patrick DL, Drossman DA, Frederick IO, et al. Quality of life in persons with irritable bowel syndrome: development and validation of a new measure. Dig Dis Sci 1998 Feb; 43 (2): 400–11
Steward AL, Greenfield S, Hays RD, et al. Functional status and well being of patients with chronic conditions: results from the medical outcomes study. JAMA 1989; 262: 907–13
Bergner M, Bobbitt RA, Pollard WE, et al. The sickness impact profile: validation of a health status measure. Med Care 1976; 14 (1): 57–67
Borgaonkar MR, Irvine EJ. Quality of life measurement in gastrointestinal and liver disorders. Gut 2000; 47: 444–54
Hahn BA, Kirchdoerfer LJ, Fullerton S, et al. Evaluation of a new quality of life questionnaire for patients with irritable bowel syndrome. Aliment Pharmacol Ther 1997 Jun; 11 (3): 547–52
Whitehead WE, Burnett CK, Edwin WC, et al. Impact of irritable bowel syndrome on quality of life. Dig Dis Sci 1996; 41 (11): 2248–53
Chassany O, Marquis P, Scherrer B, et al. Validation of a specific quality of life questionnaire for functional digestive disorders. Gut 1999; 44: 527–33
Irvine EJ. The quality of quality of life. Gut 1999; 44: 450–1
Wong E, Guyatt GH, Cook DJ, et al. Development of a questionnaire to measure quality of life in irritable bowel syndrome. Eur J Surg Suppl 1998; (583): 50–6
Eypasch E, Williams JI, Wood-Dauphinee S, et al. Gastrointestinal quality of life index: development, validation and application of a new instrument. Br J Surg 1995 Feb; 82 (2): 216–22
Shaw M, Talley NJ, Adlis S, et al. Development of a digestive health status instrument: tests of scaling assumptions, structure and reliability in a primary care population. Aliment Pharmacol Ther 1998 Nov; 12 (11): 1067–78
Wiklund IK, Glise H. Quality of life in different gastrointestinal conditions. Eur J Surg Suppl. 1998; 582: 56–61
Drossman DA, Li Z, Leserman J. Health status by gastrointestinal diagnosis and abuse history. Gastroenterology 1996; 110 (4): 999–1007
Dancey CP, Backhouse S. Towards a better understanding of patients with irritable bowel syndrome. J Adv Nursing 1993; 18: 1443–50
Hahn BA, Kirchdoerfer LJ, Fullerton S, et al. Patient perceived severity of irritable bowel syndrome in relation to symptoms, health care utilization and quality of life. Aliment Pharmacol Ther 1997; 11: 553–9
Stassels SA, Hahn BA. Short Form 36 (SF-36) scores in patients with IBS compared with US norms. Gastroenterology 1997; 112 Suppl.: A44
Chassany O, Marquis P, Fraitag B, et al. European psychometric validation of a specific quality of life questionnaire in functional digestive disorders [abstract]. Gut 1996; 99 (Suppl. 3): A33
Chassany O, Bergmann JF. Quality of life in irritable bowel syndrome, effect of therapy. Eur J Surg Suppl 1998; 583: 81–6
Gralnek IM, Hays RD, Kilbourne A, et al. The impact of irritable bowel syndrome on health related quality of life. Gastroenterology 2000; 119: 654–60
Koloski NA, Talley NJ, Boyce PM. The impact of functional gastrointestinal disorders on quality of life. Am J Gastroenterol 2000 Jan; 95 (1): 67–71
Drossman DA, Li Z, Toner BB, et al. Functional bowel disorders: a multicentre comparison of health status and development of illness severity index. Dig Dis Sci 1995; 40: 986–95
Talley NJ, Zinsmeister AR, Melton LJ. Irritable bowel syndrome in a community: subgroups risk factors and health care utilization. Am J Epidemiol 1995; 142: 76–83
Glia A, Lindberg G. quality of life in patients with different types of functional constipation. Scand J Gastroenterol 1997; 32: 1083–9
Drossman DA, Creed FH, Fava GA. Psychosocial aspects of functional gastrointestinal disorders. Gastroenterol Int 1995; 8: 47–90
Walker EA, Gelfand AN, Gelfand MD. Psychiatric diagnoses, sexual and physical victimisation and disability in patients with irritable bowel syndrome or inflammatory bowel disease. Psychol Med 1995; 25 (6): 1259–67
Drossman DA, McKee DC, Sandler RS. Psychological factors in the irritable bowel syndrome. Gastroenterology 1988; 95: 701–8
Lydiard RB, Fossey MD, March W. Prevalence of psychiatric disorders in patients with IBS. Psychosomatics 1993; 34: 229–34
Drossman DA, Leserman J, Nachman G. Sexual and physical abuse in women with functional than organic gastrointestinal disorders. Ann Intern Med 1990; 113: 828–33
Talley NJ, Fett SL, Zinsmeister AR, et al. Gastrointestinal tract symptoms and self-reported abuse: a population-based study. Gastroenterology 1994; 107 (4): 1040–9
Longstreth GF, Wolde-Tsadik G. Irritable bowel type symptoms in HMO examinees. Dig Dis Sci 1993; 38: 1581–9
Creed F, Craig T, Farmer R. Functional abdominal pain, psychiatric illness and life events. Gut 1988; 29 (2): 235–42
Craig TKJ, Brown GW. Goal frustration and life events in the aetiology of painful gastrointestinal disorder. J Psychosom Res 1984; 28: 411–21
Whitehead WE, Crowell MD, Robinson JC. Effects of stressful life events on bowel symptoms: subjects with irritable bowel syndrome compared with subjects without bowel dysfunction. Gut 1992; 33: 825–30
Barton A, Pal B, Whorwell PJ, et al. Increased prevalence of sicca complex and fibromyalgia in patients with irritable bowel syndrome. Am J Gastroenterol 1999; 94 (7): 1898–901
Whorwell PJ, McCallum M, Creed FH, et al. Non-colonic features of irritable bowel syndrome. Gut 1986; 27: 37–40
Sperber AD, Atzmon Y, Neumann L, et al. Fibromyalgia in the irritable bowel syndrome: studies of prevalence and clinical implications. Am J Gastroenterol 1999; 94 (12): 3541–6
Hahn BA, Yan S, Stassels S. Impact of irritable bowel syndrome on quality of life and resource use in the United States & United Kingdom. Digestion 1999; 60: 77–81
O’Keefe EA, Talley NJ, Zinsmeister AR, et al. Bowel disorders impair functional status and quality of life in the elderly: a population based study. J Gerontol A Biol Sci Med Sci 1995 Jul; 50 (4): M184–9
Drossman DA, Whitehead WE, Camilleri M. Irritable bowel syndrome: a technical review for practice guideline development. Gastroenterology 1997; 112 (6): 2120–37
Switz DM. What a gastroenterologist does all day: a survey of a state society’s practice. Gastroenterology 1976; 70: 1048
Wells NE, Hahn BA, Whorwell PJ. Clinical economics review: irritable bowel syndrome. Aliment Pharmacol Ther 1997; 11 (6): 1019–30
Everhart JE, Renault PF. Irritable bowel syndrome in office based practice in the United States. Gastroenterology 1991; 100: 998–1005
Maxton DG, Whorwell PJ. Use of medical resources and attitudes to health care in patients with chronic abdominal pain. Br J Med Econ 1992; 2: 75–9
Whitehead WE, Cheskin LJ, Heller BR. Evidence for exacerbation of irritable bowel syndrome during menses. Gastroenterology 1990; 98: 1485
Talley NJ, Gabriel SE, Harmsen WS, et al. Medical costs in community subjects with irritable bowel syndrome. Gastroenterology 1995; 109: 1736–41
KMPG Peat Marwick Inc. The economic burden of irritable bowel syndrome in Canada. Symposium on functional digestive disease 1997; 34: 10
Drossman DA, Li Z, Andruzzi E. US householder survey of functional gastrointestinal disorders. Prevalence, sociodemography and health impact. Dig Dis Sci 1993; 38 (9): 1569–80
Schuster MM. Diagnostic evaluation of the irritable bowel syndrome. Gastroenterol Clin North Am 1991; 20: 269
Klein KB. Controlled treatment trials in the irritable bowel syndrome: a critique. Gastroenterology 1988; 95: 232–41
King TS, Hunter JO. quality of life in irritable bowel syndrome: does it improve with resolution of symptoms? Gastroenterology 1997; 112 Suppl.: A761
Mathias JR, Clench MH, Abell TE, et al. Effects of leuprolide acetate on functional bowel disease: a multicentre, double blind, placebo-controlled study. Gastroenterology 1997; 112 Suppl.: A784
Dapoigny M, Abitbol JL, Meric G, et al. Fedotozine in IBS: results of a six week placebo controlled multicentre therapeutic trial. Gastroenterology 1995; 108 Suppl.: A588
Chassany O, Geneve J, Abitbol JL, et al. Specific quality of life questionnaire in IBS: effect of fedotozine. Gastroenterology 1995; 108 Suppl.: A581
Drossman DA, Creed FH, Olden KW, et al. Psychosocial aspects of the functional gastrointestinal disorders. In: Drossman DA, Talley NJ, Thompson WG, et al., editors. The functional gastrointestinal disorders: diagnosis pathophysiology & treatment: a multinational consensus. Vol 2. Mclean (VA): Degnon and associates. In press
Guthrie E, Creed F, Dawson D, et al. A controlled trial of psychological treatment for the irritable bowel syndrome. Gastroenterology 1991; 100: 450–7
Talley NJ, Owen BK, Boyce P, et al. Psychological treatments for irritable bowel syndrome: a critique of controlled treatment trials. Am J Gastroenterol 1996; 91: 277–83
Galovski TE, Blanchard EB. The treatment of irritable bowel syndrome with hypnotherapy. Appl Psychophysiol Biofeedback 1998; 23: 219–32
Whorwell PJ, Prior A, Faragher EB. Controlled trial of hypnotherapy in the treatment of severe refractory irritable bowel syndrome. Lancet 1984; 2 (8414): 1232–4
Whorwell PJ, Prior A, Colgan SM. Hypnotherapy in severe irritable bowel syndrome: further experience. Gut 1987; 28: 423–5
Houghton LA, Heyman DJ, Whorwell PJ. Symptomatology, quality of life and economic features of irritable bowel syndrome — the effect of hypnotherapy. Aliment Pharmacol Ther 1996; 10: 91–5
Harvey RF, Hinton RA, Gunery RM, et al. Individual and group hypnotherapy in the treatment of refractory IBS. Lancet 1989; 1: 424–5
Chiotakakau-Faliakau E, Kamm MA, Ray AJ, et al. Biofeedback provides long term benefit for patients with intractable, slow and normal transit constipation. Gut 1998; 42: 517–21
Wiklund I. Quality of life and regulatory issues. Scand J Gastroenterol 1996; 31 Suppl. 221: 37–8
Acknowledgements
Dr Whorwell acts as an adviser to a number of pharmaceutical companies including GlaxoSmithKline, Novartis and Solvay.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lea, R., Whorwell, P.J. Quality of Life in Irritable Bowel Syndrome. Pharmacoeconomics 19, 643–653 (2001). https://doi.org/10.2165/00019053-200119060-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00019053-200119060-00003